Elypta
company
About
Preventing cancer mortality by developing a metabolism-based liquid biopsy platform for early detection and monitoring
- 11 - 50
Details
- Last Funding Type
- Series A
- Last Funding Money Raised
- $21M
- Industries
- Biotechnology,Health Care,Health Diagnostics
- Founded date
- May 1, 2017
- Number Of Employee
- 11 - 50
- Operating Status
- Active
Elypta is developing a metabolism-based liquid biopsy platform based on a new IVD laboratory assay kit and artificial intelligence algorithms trained by their clinical database.Elypta proudly sponsors the clinical trial series AURORAX to investigate applications in their lead indication renal cell carcinoma from surveillance of recurrence to monitoring treatment response. They also explore several other indications to understand the full potential for Elypta’s platform.
Funding Rounds
Number of Funding Rounds
Total Funding Amount
2
$21M kr65M
Elypta has raised a total of
$21M kr65M
in funding over 2 rounds. Their latest funding was raised on
Jun 20, 2022 from a Series A round.
| Announced Date | Round | Money Raised | Number of Investors | Lead Investors | Post Valuation | |
|---|---|---|---|---|---|---|
| Jun 20, 2022 | Series A | $21M | 2 | — | — | Detail |
| Jan 23, 2020 | Seed | kr65M | 1 | — | — | Detail |
Investments
Number of Investments
Number of Lead Investments
1
0
Elypta has made 1 investments. Their most recent investment was on
Dec 16, 2015, when Springboard raised $1.70M.
|
Date
Company Name
|
Round | Money Raised | Industry | Lead Investor |
|---|---|---|---|---|
|
Dec 16, 2015
Springboard
|
Seed | $1.70M | E-Learning | — |
Investors
Number of Lead Investors
Number of Investors
—
2
Elypta is funded by 2 investors.
Hillclimber
and Norrsken VC
are the most recent investors.
| Investor Name | Lead Investor | Funding Round |
|---|---|---|
|
|
— | Series A |
Norrsken VC
|
— | Series A |
Share
Twitter
LinkedIn
Line
Facebook
Telegram
Email
Page Link
